US

News and Press Releases

February 2021
26/02/2021
Chiesi Global Rare Diseases Recognizes Rare Disease Day Highlighting Importance of Staying Connected for Information and Support
Company sponsors #wewearstripes social media campaign calling on participants to share photos to express support for people affected by rare diseases   Company to light up offices around the world including Italy, the United States, and Canada   BOSTON, Mass. - February 26, 2021 - Chiesi Global Rare Diseases, a business unit of...
btnboxnews.png
23/02/2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry Disease
Study achieved key objectives for safety, efficacy and pharmacokinetics   After completion of the study, all patients enrolled in an extension study   pegunigalsidase alfa (PRX-102) provided coverage to patients for the entire 4-week period in treated patients   No new patients developed treatment-induced anti-drug antibodies...
btnboxnews.png
10/02/2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium™ 2021
Phase III BRIDGE open-label, switch-over clinical trial met key objectives for safety and efficacy Mean overall annualized change in estimated Glomerular Filtration Rate (eGFR slope) improved from -5.9 to -1.2 mL/min/1.73 m2/year 12-months on-treatment Phase III BRIDGE study final results suggest a potential benefit of pegunigalsidase alfa...
btnboxnews.png
December 2020
30/12/2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease
Phase III BRIDGE open-label, switch-over clinical trial met key objectives for safety and efficacy   Final analysis confirmed substantial improvement in renal function as measured by mean annualized estimated Glomerular Filtration Rate (eGFR slope) in patients switched from agalsidase alfa to pegunigalsidase alfa (PRX-102)   A...
btnboxnews.png
23/12/2020
Chiesi Global Rare Diseases Announces First Patient Treated in Expanded Access Program for Pegunigalsidase Alfa for Proposed Treatment of Fabry Disease
Program grants access to investigational therapy for Fabry disease patients in the United States who cannot be adequately treated with currently available FDA-approved drugs -   Boston, MA, (December 23, 2020) – Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare...
btnboxnews.png
November 2020
27/11/2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
CARMIEL, Israel, November 27, 2020 /PRNewswire/ - Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, and Chiesi Global Rare...
btnboxnews.png
24/11/2020
Chiesi Group Acquires Unikeris Limited and Adds Revcovi® (elapegademase-lvlr) Injection to Product Portfolio
Addition of approved therapy for treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID)expands Chiesi commitment to addressing significant areas of unmet need in treatment of rare diseases Under terms of the agreement Chiesi Group has acquired all rights to Revcovi, which will continue to be available to patients through...
btnboxnews.png
October 2020
13/10/2020
Chiesi Global Rare Diseases Launches “Rethink Fabry” Campaign to Bring Important Information to Fabry Disease Community and Support Patients and Caregivers
Disease education program aims to help patients, caregivers and families affected by Fabry disease to make informed healthcare decisions Program includes new resources for healthcare professionals to support strategies in diagnosis and disease management   Boston, MA (October 13, 2020) – Chiesi Global Rare Diseases, a business unit...
btnboxnews.png
02/10/2020
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Launch of Expanded Access Program in the United States for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
Program grants access to investigational treatment for Fabry disease patients that cannot be adequately treated with any FDA-approved drugs and provides guidance to treating physicians   Boston, MA and Carmiel, Israel, (02/10/2020) – Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international...
btnboxnews.png
August 2020
24/08/2020
Protalix BioTherapeutics Announces Completion of the Treatment Period for its Phase III BRIGHT Clinical Trial of Pegunigalsidase Alfa (PRX-102) for the Proposed Treatment of Fabry Disease
Top-line data anticipated in 4Q2020 upon completion of final monitoring visits CARMIEL, Israel, August 24, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary...
btnboxnews.png
11/08/2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of Biologics License Application (BLA) for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease and Grants Priority Review
CARMIEL, Israel, Aug. 11, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, or the Company,...
btnboxnews.png
July 2020
10/07/2020
Bioasis and Chiesi Group to Host Webcast on July 16, 2020
GUILFORD, CONN., U.S.A. and PARMA, ITALY – BIOASIS TECHNOLOGIES INC. (“Bioasis”) (TSXV:BTI.V; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TMplatform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and...
btnboxnews.png
June 2020
29/06/2020
Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance
Deal provides Chiesi Group with worldwide, exclusive license to use Bioasis xB3 TM platform for delivery of undisclosed enzymes in treatment of four lysosomal storage disorders.   Under terms of the agreement, Bioasis will receive an upfront payment of US$3 million, additional potential milestone payments of up to US$138 million and...
btnboxnews.png
May 2020
20/05/2020
Chiesi Group Receives FDA Approval for Ferriprox® (deferiprone) twice-a-day tablets
BOSTON, May 21, 2020 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), today announced that the U.S. Food and Drug Administration (FDA) has approved Ferriprox® (deferiprone) twice-a-day tablets for the treatment of patients...
btnboxnews.png
February 2020
06/02/2020
Chiesi Group Announces Establishment of New Global Rare Diseases Division
Specialized division focused on research and product development for rare and ultra-rare diseases highlights Chiesi’s commitment to building a brighter future for patients Chiesi Global Rare Diseases unit will harness the full resources of Chiesi Group to support rare disease communities, with initial focus on lysosomal storage disorders,...
btnboxnews.png